Ibio (NASDAQ:IBIO – Get Free Report) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Wednesday.
Ibio Price Performance
About Ibio
iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis.
See Also
- Five stocks we like better than Ibio
- Stock Splits, Do They Really Impact Investors?
- After Gold Blast Soars Past $4,000, BofA Eyes $5,000 in 2026
- What is a Microcap Stock? Everything You Need to Know
- Buyback Boom: 3 Companies Betting Big on Themselves
- The 3 Best Fintech Stocks to Buy Now
- Analysts Flock to Upgrade DELL After Big AI-Server Guidance Boost
Receive News & Ratings for Ibio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ibio and related companies with MarketBeat.com's FREE daily email newsletter.
